![]() |
市场调查报告书
商品编码
1494320
亚太地区 ELISA 诊断测试市场预测至 2030 年 - 区域分析 - 按采用、测试类型、应用程式和最终用户Asia Pacific ELISA Diagnostics Tests Market Forecast to 2030 - Regional Analysis - by Adoption, Test Type, Application, and End User |
2022年亚太地区ELISA诊断测试市值为2.557亿美元,预计2030年将达到5.0308亿美元;预计2022年至2030年复合年增长率为8.8%。
创新产品推出支撑亚太 ELISA 诊断测试市场
ELISA 因其灵活性、灵敏度和易于使用等多种优点而成为最受欢迎的免疫分析测试之一。此外,ELISA 检测试剂盒的低成本以及与高通量检测相关的多方面适用性使其成为满足各种研究和 IVD 要求的理想解决方案。凭藉低成本的适用性,检测试剂盒的产品创新增强了对人类和动物研究的需求。此外,製造商也专注于利用内部设施开发 ELISA 检测试剂盒。 Innovative Research 公司销售多种 ELISA 试剂盒,可选择性地辨识多种凝血剂、物种和抗体。 「Human Factor IX Kit」就是 Innovative Research 生产的一个这样的例子。人类凝血因子 IX 抗原测定旨在定量测定人类血浆中总因子 IX 抗原。此试剂盒建议仅用于研究目的,试剂最多可用于 96 项临床测试。此外,在 COVID-19 大流行期间,製造商推出了 ELISA 测试的创新产品,加速了 ELISA 测试在人类中的采用。 2022 年 12 月,Pictor Limited 宣布推出「PictArray SARS-CoV-2 抗体测试」新产品,该产品已展示了针对患者和医生的真正临床实用性。新产品可检测与 COVID-19 病毒相关的感染,产生的临床结果可帮助患者和医生治疗和管理 SARS-CoV-2 感染。製造商推出的创新 ELISA 检测试剂盒有望以低成本和多方面的应用为诊断与不同类型物种相关的各种感染提供有效的临床结果。因此,从长远来看,创新产品的推出将为製造商提供利润丰厚的机会。
亚太地区 ELISA 诊断测试市场概览
中国拥有强大而有弹性的公共卫生系统,能够在传染病威胁成为流行病之前迅速预防、发现和应对。中国的生态环境带来了新出现、重新出现和新型疾病的风险,这些疾病可能威胁到中国和世界其他地区,因为中国拥有约 14 亿的庞大人口和占世界 50% 的牲畜。 《全球健康杂誌》2023年9月发表的一篇文章对中国东南部江苏省法定传染病的年发病率和死亡率进行了研究。研究得出的结论是,公共卫生政策在研究期间有效降低了肠道疾病、媒介传播疾病和人畜共患疾病的发病率以及相关的死亡率,但性传染病和血液传播疾病(主要是梅毒和爱滋病)的发生率,增加了。
此外,世界各地不断增长的航空旅行网络极大地增加了感染快速传播的风险,包括可能导致流行病的感染,例如 COVID-19 大流行,从而导致全球贸易中断、病例增加或死亡人数增加。该国预计将为参与该国 ELISA 诊断测试市场的本地和国际参与者提供利润丰厚的机会。
亚太地区 ELISA 诊断测试市场收入及 2030 年预测(百万美元)
亚太地区 ELISA 诊断测试市场细分
亚太地区 ELISA 诊断测试市场根据采用情况、测试类型、应用程式、最终用户和国家进行细分。根据采用情况,亚太地区 ELISA 诊断测试市场分为人类和兽医市场。 2022 年,人类细分市场将占据更大的市场份额。
就测试类型而言,亚太地区ELISA诊断测试市场分为夹心ELISA、间接ELISA、竞争性ELISA以及多重便携式ELISA。 2022 年,间接 ELISA 细分市场占据最大的市场份额。
根据应用,亚太地区 ELISA 诊断测试市场分为自体免疫疾病、传染病、癌症诊断、蛋白质定量等。 2022 年,传染病领域占据最大的市场份额。
按最终用户划分,亚太地区 ELISA 诊断测试市场分为医院和诊断中心、製药和生物技术公司、兽医医院和诊断实验室等。 2022 年,医院和诊断中心细分市场占据最大的市场份额。
按国家/地区划分,亚太地区 ELISA 诊断测试市场分为中国、日本、印度、澳洲、韩国和亚太地区其他地区。 2022年,中国在亚太地区ELISA诊断检测市场占有率中占据主导地位。
Bio-Rad Laboratories Inc.、Idex Laboratories Inc.、F. Hoffmann-La Roche Ltd.、Thermo Fisher Scientific Inc.、Abbott Laboratories、Danaher Corp.、Pictor Ltd.、DiaSorin SpA、Elabscience Biotechnology Inc. 与 Bio-Techne Corp是亚太ELISA 诊断测试市场上的一些领先公司。
The Asia Pacific ELISA diagnostics tests market was valued at US$ 255.70 million in 2022 and is expected to reach US$ 503.08 million by 2030; it is estimated to grow at a CAGR of 8.8% from 2022 to 2030.
Innovative Product Launches Bolster Asia Pacific ELISA Diagnostics Tests Market
ELISA is one of the most popular immunoassay tests owing to its various advantages such as flexibility, sensitivity, and easy-to-use features. Also, low cost of ELISA test kit and multifaceted applicability associated with high-throughput testing make it an ideal solution for various research and IVD requirements. With low-cost applicability, product innovations in the test kits enhance the demand for human and animal research. Also, manufacturers focus on developing ELISA test kits with in-house facilities. Innovative Research company sells a wide range of ELISA kits with selectivity to a broad range in identifying coagulants, species, and antibodies. "Human Factor IX Kit" is one such example manufactured by Innovative Research. The human coagulation Factor IX antigen assay is intended for the quantitative determination of total Factor IX antigen in human plasma. The kit is recommended to use only for research purposes, and reagents can be utilized for up to 96 clinical tests. Additionally, innovative product launches for ELISA tests by the manufacturers amid the COVID-19 pandemic accelerate the adoption of ELISA testing among humans. In December 2022, Pictor Limited announced a new product launch of the "PictArray SARS-CoV-2 Antibody Test," which has demonstrated real clinical utility intended for patients and doctors. The new product detects the infection associated with the COVID-19 virus, and the clinical results produced assist the patients and doctors in treating and managing SARS-CoV-2 infection. Launches of innovative ELISA test kits by manufacturers are expected to provide effective clinical results for diagnosing varied infections associated with different types of species with low cost and multifaceted applications. Thus, innovative product launches would provide lucrative opportunities for manufacturers in the long run.
Asia Pacific ELISA Diagnostics Tests Market Overview
China has a strong and resilient public health system that can rapidly prevent, detect, and respond to infectious disease threats before they become epidemics. China's ecology poses a risk for emerging, re-emerging, and novel diseases that could threaten China and the Rest of world owing to the vast population of ~ 1.4 billion and 50% of the world's livestock. In an article published by Journal of Global Health in September 2023, a study was carried out on annual incidence and fatality rates of notifiable infectious diseases in Jiangsu province of southeast China. The study concluded that public health policies have been effective in reducing the incidence of intestinal, vector-borne, and zoonotic diseases during the study period and the associated fatality, but that the incidence of sexually transmitted and blood-borne diseases, mainly syphilis and AIDS, has increased.
Additionally, growing network of air travel routes across the world dramatically increases the risk of rapid infection spread, including infections that may lead to pandemics, such as the COVID-19 pandemic, that result in disruption of global trade, rise in illness cases, or increase in deaths. The country is expected to provide lucrative opportunities to local and international players involved in ELISA diagnostics test market in the country.
Asia Pacific ELISA Diagnostics Tests Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific ELISA Diagnostics Tests Market Segmentation
The Asia Pacific ELISA diagnostics tests market is segmented based on adoption, test type, application, end user, and country. Based on adoption, the Asia Pacific ELISA diagnostics tests market is bifurcated into human and veterinary. The human segment held a larger market share in 2022.
In terms of test type, the Asia Pacific ELISA diagnostics tests market is segmented into sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held the largest market share in 2022.
Based on application, the Asia Pacific ELISA diagnostics tests market is segmented into autoimmune diseases, infectious diseases, cancer diagnosis, protein quantification, and others. The infectious diseases segment held the largest market share in 2022.
By end user, the Asia Pacific ELISA diagnostics tests market is segmented into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospitals & diagnostic laboratories, and others. The hospitals & diagnostic centers segment held the largest market share in 2022.
Based on country, the Asia Pacific ELISA diagnostics tests market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific ELISA diagnostics tests market share in 2022.
Bio-Rad Laboratories Inc., Idexx Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corp., Pictor Ltd., DiaSorin SpA, Elabscience Biotechnology Inc., and Bio-Techne Corp are some of the leading companies operating in the Asia Pacific ELISA diagnostics tests market.